Glenmede Trust Company »

Dianthus Therapeutics shares owned by Glenmede Trust Company

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Glenmede Trust Company from 13F filings

Historical chart of Glenmede Trust Company investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Glenmede Trust Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Glenmede Trust Company

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.0M 13k 83.92
2025-12-31 $262k 6.3k 41.21

More positions owned by Glenmede Trust Company

Vanguard Index Fds S&p 500 Etf S&p 500 Etf Shs (VOO)
Apple (AAPL)
Ishares S & P Smallcap 600 Core S&p Scp Etf (IJR)
Microsoft Corporation (MSFT)
Call On Spy 12/18/26 @ 680 Tr Unit Call Option (SPY)
Alphabet Inc Cap Stk Cl A Cap Stk Cl A (GOOGL)
Johnson & Johnson (JNJ)
JPMorgan Chase & Co. (JPM)
Ishares Russell 2500 Etf Rusel 2500 Etf (SMMD)
Putnam Focused Large Cap Value Etf Focused Lar Cap (PVAL)
Alphabet Inc Cap Stk Cl C Cap Stk Cl C (GOOG)
Eli Lilly & Co. (LLY)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Vanguard Index Fds Small Cap Etf Small Cp Etf (VB)

View all positions for Glenmede Trust Company

Top funds holding Dianthus Therapeutics

FMR
BlackRock
RA Capital Management
Fairmount Funds Management
Wellington Management Company
Avidity Partners Management
Vanguard Group
Vanguard Capital Management
Octagon Capital Advisors
TCG Crossover Management
Citadel Advisors
State Street Corporation
VR Adviser
Fred Alger Management
Deerfield Management Company

View all funds holding Dianthus Therapeutics